01.08.2019
Provision of the Registration Document (R 19-030) and Statement of cash position as of June 30, 2019 (in French)
Download
03.07.2019
VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA®, now the first product proven effective in people with prediabetes
Download
24.06.2019
VALBIOTIS participates in the first HealthTech Investor Days, organized by France Biotech
Download
07.06.2019
VALBIOTIS to present novel data about TOTUM-63 and metabolic diseases prevention at the 2019 scientific sessions of the American Diabetes Association
Download
28.05.2019
VALBIOTIS succeeds in the industrial production of VALEDIA®, a major scientific innovation for prediabetic people, in collaboration with the Pierre Fabre group
Download
14.05.2019
VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA® before 31 July 2019
Download
